Skip to main content

Advertisement

Table 4 One-year survival and one-year mortality rate ratio (MRR) by level of comorbidity according to the stage of cancer and adjusted for age and calendar time.

From: The impact of comorbidity and stage on ovarian cancer mortality: A nationwide Danish cohort study

  Charlson Comorbidity score
  0 1–2 3+
Localized tumour/FIGO-stage I    
Number 774 184 37
Median age, years 56 67 72
   Survival in % 95 (93–97) 88 (82–92) 81 (64–91)
   Crude MRR 1 (ref.) 2.8 (1.6–4.6) 4.5 (2.0–10.0)
   Adj. MRR 1 (ref.) 2.1 (1.2–3.5) 2.7 (1.2–6.2)
Regional spread/FIGO-stage II, III    
Number 1,757 492 157
Median age, years 62 68 69
   Survival in % 77 (75–79) 63 (59–67) 47 (39–54)
   Crude MRR 5.3 (3.8–7.4) 9.2 (6.5–13.2) 16.0 (10.9–23.6)
   Adj. MRR 4.8 (3.5–6.8) 7.1 (5.0–10.1) 12.3 (8.3–18.1)
Distant metastases/FIGO-stage IV    
Number 1,002 338 140
Median age, years 66 71 71
   Survival in % 50 (47–53) 38 (33–44) 34 (27–42)
   Crude MRR 14.1 (10.1–19.7) 20.4 (14.4–28.9) 23.4 (16.0–34.2)
   Adj. MRR 11.6 (8.3–16.2) 13.9 (9.8–19.8) 15.7 (10.7–23.1)
Unspecified    
Number 194 102 36
Median age, years 66 75 71
   Survival in % 62 (55–68) 40 (31–50) 33 (19–49)
   Crude MRR 10.1 (6.8–15.0) 19.2 (12.8–28.9) 25.0 (15.0–41.8)
   Adj. MRR 8.1 (5.5–12.1) 11.2 (7.4–16.8) 15.3 (9.1–25.7)
  1. The reference group was patients with localized tumour/FIGO I and no registered comorbidity. The corresponding 95% confidence interval is given in parentheses.